TABLE 4.

Adjusted^a epidemiologic characteristics of pyrazinamide resistance among MDR and non-MDR TB cases

Characteristic	OR	95% CI	P value
MDR
Age (yr%)	0.98	0.95–1.01	0.1518
HIV positivity	1.38	0.57–3.37	0.4724
TB infection site
Extrapulmonary vs pulmonary	0.83	0.16–4.23	0.8211
Both vs pulmonary	0.44	0.12–1.60	0.2149
AFB smear	1.79	0.66–4.87	0.2556
History of LTBI	0.12	0.01–1.07	0.0572
EMB-SLD	3.48	1.57–7.69	0.0021
Non-MDR
Age (yr)	0.99	0.98–1.01	0.5188
HIV positivity	0.95	0.46–1.98	0.8891
TB infection site
Extrapulmonary vs pulmonary	0.89	0.28–2.81	0.8379
Both vs pulmonary	1.37	0.63–2.97	0.4256
AFB smear	1.82	0.93–3.58	0.0820
Lineage 1	3.27	1.64–6.51	0.0008

^aAdjusted for known TB risk factors, including age, HIV, and any univariate variable with a P value of <0.2.